Caseware UK (AP4) 2024.0.164 2024.0.164 2024-12-312024-12-31falsefalse2false2023-07-13trueThe members have not required the company to obtain an audit in accordance with section 476 of the Companies Act 2006. 15002108 2023-07-12 15002108 2024-12-31 15002108 2023-07-13 2024-12-31 15002108 2022-07-13 2023-07-12 15002108 c:Director1 2023-07-13 2024-12-31 15002108 c:Director2 2023-07-13 2024-12-31 15002108 d:CurrentFinancialInstruments 2024-12-31 15002108 d:Non-currentFinancialInstruments 2024-12-31 15002108 d:CurrentFinancialInstruments d:WithinOneYear 2024-12-31 15002108 d:Non-currentFinancialInstruments d:AfterOneYear 2024-12-31 15002108 d:ShareCapital 2024-12-31 15002108 d:RetainedEarningsAccumulatedLosses 2024-12-31 15002108 c:FRS102 2023-07-13 2024-12-31 15002108 c:AuditExempt-NoAccountantsReport 2023-07-13 2024-12-31 15002108 c:FullAccounts 2023-07-13 2024-12-31 15002108 c:PrivateLimitedCompanyLtd 2023-07-13 2024-12-31 15002108 e:PoundSterling 2023-07-13 2024-12-31 iso4217:GBP xbrli:pure
Registered number: 15002108


BIOMR LIMITED








UNAUDITED

FINANCIAL STATEMENTS

FOR THE PERIOD 13 JULY 2023 TO  31 DECEMBER 2024

 
BIOMR LIMITED
REGISTERED NUMBER:15002108

BALANCE SHEET
AS AT 31 DECEMBER 2024

2024
Note
£

  

Current assets
  

Debtors: amounts falling due within one year
  
16,109

Cash at bank and in hand
  
61,371

  
77,480

Creditors: amounts falling due within one year
  
(39,533)

Net current assets
  
 
 
37,947

Total assets less current liabilities
  
37,947

Creditors: amounts falling due after more than one year
  
(244,932)

  

Net (liabilities)/assets
  
(206,985)


Capital and reserves
  

Called up share capital 
  
80

Profit and loss account
  
(207,065)

  
(206,985)


Page 1

 
BIOMR LIMITED
REGISTERED NUMBER:15002108
    
BALANCE SHEET (CONTINUED)
AS AT 31 DECEMBER 2024

The directors consider that the Company is entitled to exemption from audit under section 477 of the Companies Act 2006 and members have not required the Company to obtain an audit for the period in question in accordance with section 476 of the Companies Act 2006.

The directors acknowledge their responsibilities for complying with the requirements of the Companies Act 2006 with respect to accounting records and the preparation of financial statements.

The financial statements have been prepared in accordance with the provisions applicable to companies subject to the small companies regime and in accordance with the provisions of FRS 102 Section 1A - small entities.

The financial statements have been delivered in accordance with the provisions applicable to companies subject to the small companies regime.

The Company has opted not to file the statement of income and retained earnings in accordance with provisions applicable to companies subject to the small companies' regime.

The financial statements were approved and authorised for issue by the board and were signed on its behalf by: 




Samuel Grisa
Jordi Ferrer Orri
Director
Director


Date: 13 April 2025
Date:13 April 2025

The notes on pages 3 to 5 form part of these financial statements.

Page 2

 
BIOMR LIMITED
 
 
NOTES TO THE FINANCIAL STATEMENTS
FOR THE PERIOD ENDED 31 DECEMBER 2024

1.


General information

Biomr Limited is a private company limited by shares, incorporated in England and Wales, registration number 15002108 . The address of the principal place of business is 71 Hillgate Place, London, W8 7SS.

2.Accounting policies

 
2.1

Basis of preparation of financial statements

The financial statements have been prepared on a basis other than the historical cost convention,
and in accordance with Section 1A of Financial Reporting Standard 102, the Financial Reporting
Standard applicable in the UK and the Republic of Ireland and the Companies Act 2006. This basis
includes, where applicable, writing the company's assets down to net realisable value, and reviewing
any post balance sheet commitments which may need to be provided for.
 

The following principal accounting policies have been applied:

 
2.2

Going concern

These financial statements have not been prepared on a going concern basis. The directors have decided to cease trading and are in the process of winding down the company’s operations. Accordingly, the assets have been stated at their estimated net realisable value and provisions have been made for any known liabilities and costs associated with closure.

 
2.3

Research and development

In the research phase of an internal project it is not possible to demonstrate that the project will generate future economic benefits and hence all expenditure on research shall be recognised as an expense when it is incurred. Intangible assets are recognised from the development phase of a project if and only if certain specific criteria are met in order to demonstrate the asset will generate probable future economic benefits and that its cost can be reliably measured. The capitalised development costs are subsequently amortised on a straight-line basis over their useful economic lives, which range from 3 to 6 years.
If it is not possible to distinguish between the research phase and the development phase of an internal project, the expenditure is treated as if it were all incurred in the research phase only.

 
2.4

Debtors

Short-term debtors are measured at transaction price, less any impairment. Loans receivable are measured initially at fair value, net of transaction costs, and are measured subsequently at amortised cost using the effective interest method, less any impairment.

 
2.5

Cash and cash equivalents

Cash is represented by cash in hand and deposits with financial institutions repayable without penalty on notice of not more than 24 hours. Cash equivalents are highly liquid investments that mature in no more than three months from the date of acquisition and that are readily convertible to known amounts of cash with insignificant risk of change in value.

Page 3

 
BIOMR LIMITED
 
 
NOTES TO THE FINANCIAL STATEMENTS
FOR THE PERIOD ENDED 31 DECEMBER 2024

2.Accounting policies (continued)

 
2.6

Creditors

Short-term creditors are measured at the transaction price. Other financial liabilities, including bank loans, are measured initially at fair value, net of transaction costs, and are measured subsequently at amortised cost using the effective interest method.


3.


Employees

The average monthly number of employees, including directors, during the period was 2.


4.


Debtors

2024
£


Other debtors
16,109

16,109



5.


Cash and cash equivalents

2024
£

Cash at bank and in hand
61,371

61,371



6.


Creditors: Amounts falling due within one year

2024
£

Other taxation and social security
20,144

Other creditors
13,000

Accruals and deferred income
6,389

39,533


Page 4

 
BIOMR LIMITED
 
 
NOTES TO THE FINANCIAL STATEMENTS
FOR THE PERIOD ENDED 31 DECEMBER 2024

7.


Creditors: Amounts falling due after more than one year

2024
£

Other creditors
244,932

244,932


As at the balance sheet date the company had outstanding convertible loan notes which are included above in note 7, other creditors as detailed below:
1.) Issue date: 23 August 2023 investment of £145,000; no interest is charged on this note. If this note is not converted to preference shares under compeltion of an equity financing round within 36 months of the issue date, then the investor has the right to convert the investment amount into the most senior class of shares in issue in the company equal to a 10% shareholding. The note has a maturity date of 10 years.
2.) Issue date: 12 September 2023 investment of £99,932. If the investment amount has not converted to conversion shares under compeltion of an equity financing round within 36 months of the issue date, the investor may either;
 (i) elect to convert the outstanding investment amount into such number of fully paid conversion shares so that the aggregate number of shares held by the investor and any member of the same fund group, following conversion of the investment amount, represents the relevant percentage of the fully diluted capitalisation of the company immediately following the date of such optional conversion (the “Optional Conversion Date”); 
(ii) elect to be repaid the outstanding investment amount; 
or (iii) extend the maturity date. 
Due to the nature of the notes the directors have been unable to split the debt/equity element.

 
Page 5